What is intismeran, and how is it being used in the clinical study mentioned in the news?

Intismeran is an experimental mRNA-based cancer vaccine being developed by Moderna and Merck that is designed to be personalized for individual patients based on the unique mutations present in their tumors. In the current clinical study, it is being administered in combination with Keytruda, an immunotherapy drug made by Merck, specifically to treat melanoma patients.

What key finding did Moderna and Merck report about the combination of intismeran and Keytruda compared to Keytruda alone?

Moderna and Merck reported that melanoma patients who received the combination of intismeran and Keytruda experienced longer survival without cancer returning or metastasizing compared to those who received Keytruda alone. However, the companies did not disclose the specific duration of recurrence-free survival or overall survival, and stated they plan to present the full study results at an upcoming international medical meeting.

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

ChemBrief

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test — ChemBrief Topics

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

FAQ